ClinicalTrials.gov
public full text
Public Domain
ECP-1014 Treatment for Patients With Solid Tumor Cancers
The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and optimal recommended Phase 2 dose (RP2D) during a 28-day dosing period of ECP-1014 in patients with solid tumors and by evaluation of dose limiting toxicities.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors#1365798
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors#847862
- Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies#1243676
- A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors#1094018
- Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors#845405
Record · ID 1182772
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive